| A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03) (NCT07549412) | EMD Serono Research & Development Institute, Inc. | 2026-05-06 |
| A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2) (NCT07355218) | EMD Serono Research & Development Institute, Inc. | 2026-04-01 |
| A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (NCT07332481) | EMD Serono Research & Development Institute, Inc. | 2026-03-10 |
| Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors (NCT07360314) | EMD Serono Research & Development Institute, Inc. | 2026-02-13 |
| M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors (NCT07166601) | EMD Serono Research & Development Institute, Inc. | 2025-10-10 |
| A Study to Assess the Bioequivalence of Follitropin Alfa Solution in Pen and Follitropin Alfa Powder in Vial in Healthy Downregulated Male Participants (NCT07097259) | EMD Serono Research & Development Institute, Inc. | 2025-07-21 |
| Phase 1 Study of M9466 Combined With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521) (NCT06719973) | EMD Serono Research & Development Institute, Inc. | 2025-05-14 |
| Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) (NCT06710132) | EMD Serono Research & Development Institute, Inc. | 2025-01-29 |
| Anti-GD2 ADC M3554 in Advanced Solid Tumors (NCT06641908) | EMD Serono Research & Development Institute, Inc. | 2024-11-08 |
| Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302) (NCT06433219) | EMD Serono Research & Development Institute, Inc. | 2024-10-30 |
| M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511) (NCT06509906) | EMD Serono Research & Development Institute, Inc. | 2024-10-08 |
| Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has Progressed on Prior Anti-PD-(L)1 Therapy (JAVELIN DDRiver Bladder) (NCT06424717) | EMD Serono Research & Development Institute, Inc. | 2024-08-16 |
| M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501) (NCT06421935) | EMD Serono Research & Development Institute, Inc. | 2024-08-07 |
| Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX) (NCT06056310) | EMD Serono Research & Development Institute, Inc. | 2024-01-18 |
| Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322) (NCT05882734) | EMD Serono Research & Development Institute, Inc. | 2023-09-13 |
| Study of M5049 in DM and PM Participants (NEPTUNIA) (NCT05650567) | EMD Serono Research & Development Institute, Inc. | 2023-01-19 |
| Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION) (NCT05386550) | EMD Serono Research & Development Institute, Inc. | 2022-10-06 |
| A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley) (NCT05327530) | EMD Serono Research & Development Institute, Inc. | 2022-08-17 |
| Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01) (NCT05464030) | EMD Serono Research & Development Institute, Inc. | 2022-08-04 |
| Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320) (NCT05396833) | EMD Serono Research & Development Institute, Inc. | 2022-06-07 |
| The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW) (NCT05162586) | EMD Serono Research & Development Institute, Inc. | 2022-03-31 |
| First in Human Study of M1069 in Advanced Solid Tumors (NCT05198349) | EMD Serono Research & Development Institute, Inc. | 2022-03-02 |
| Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors (NCT05081180) | EMD Serono Research & Development Institute, Inc. | 2021-12-03 |
| Bintrafusp Alfa Program Rollover Study (NCT05061823) | EMD Serono Research & Development Institute, Inc. | 2021-12-01 |
| First-in-human Study of M4076 in Advanced Solid Tumors (DDRiver Solid Tumors 410) (NCT04882917) | EMD Serono Research & Development Institute, Inc. | 2021-05-24 |
| The MS-LINK™ Outcomes Study (NCT04735406) | EMD Serono Research & Development Institute, Inc. | 2021-03-24 |
| Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE) (NCT04515394) | EMD Serono Research & Development Institute, Inc. | 2021-01-28 |
| Study of M4344 in Combination With Niraparib (NCT04655183) | EMD Serono Research & Development Institute, Inc. | 2020-12-01 |
| Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTR@PID 046) (NCT04551950) | EMD Serono Research & Development Institute, Inc. | 2020-10-19 |
| Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer (NCT04489940) | EMD Serono Research & Development Institute, Inc. | 2020-10-12 |
| A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX) (NCT04459715) | EMD Serono Research & Development Institute, Inc. | 2020-08-07 |
| Study of M5049 in Participants With COVID-19 Pneumonia (ANEMONE) (NCT04448756) | EMD Serono Research & Development Institute, Inc. | 2020-07-29 |
| First in Human Study of M6223 (NCT04457778) | EMD Serono Research & Development Institute, Inc. | 2020-07-10 |
| Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer (NCT04246489) | EMD Serono Research & Development Institute, Inc. | 2020-03-30 |
| Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301) (NCT04170153) | EMD Serono Research & Development Institute, Inc. | 2019-12-20 |
| First in Human Dose Escalation of M3258 as a Single Agent and Expansion Study of M3258 in Combination With Dexamethasone (NCT04075721) | EMD Serono Research & Development Institute, Inc. | 2019-09-26 |
| Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC (NCT04066491) | EMD Serono Research & Development Institute, Inc. | 2019-09-20 |
| A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2) (NCT03940703) | EMD Serono Research & Development Institute, Inc. | 2019-09-19 |
| Study of Evobrutinib in Participants With RMS (NCT04032171) | EMD Serono Research & Development Institute, Inc. | 2019-09-10 |
| Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS) (NCT04032158) | EMD Serono Research & Development Institute, Inc. | 2019-08-26 |
| Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS) (NCT03961204) | EMD Serono Research & Development Institute, Inc. | 2019-08-15 |
| A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion DMDs for RMS (MASTER-2) (NCT03933202) | EMD Serono Research & Development Institute, Inc. | 2019-07-22 |
| A Study of Suboptimally Controlled Participants Previously Taking Injectable DMDs for RMS (CLICK-MS) (NCT03933215) | EMD Serono Research & Development Institute, Inc. | 2019-05-21 |
| M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (NCT03840902) | EMD Serono Research & Development Institute, Inc. | 2019-04-16 |
| M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC) (NCT03840915) | EMD Serono Research & Development Institute, Inc. | 2019-04-02 |
| M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer) (NCT03833661) | EMD Serono Research & Development Institute, Inc. | 2019-03-26 |
| Avelumab Program Rollover Study (NCT03815643) | EMD Serono Research & Development Institute, Inc. | 2019-03-22 |
| Study of Peposertib in Combination With Capecitabine and RT in Rectal Cancer (NCT03770689) | EMD Serono Research & Development Institute, Inc. | 2019-03-20 |
| Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer (NCT03704467) | EMD Serono Research & Development Institute, Inc. | 2019-03-04 |
| Study of Avelumab-M3814 Combinations (NCT03724890) | EMD Serono Research & Development Institute, Inc. | 2018-11-27 |
| M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC) (NCT03631706) | EMD Serono Research & Development Institute, Inc. | 2018-10-01 |
| Tepotinib Hepatic Impairment Trial (NCT03546608) | EMD Serono Research & Development Institute, Inc. | 2018-06-13 |
| Phase I/II Study of Avelumab in Pediatric Cancer Participants (NCT03451825) | EMD Serono Research & Development Institute, Inc. | 2018-03-07 |
| First-in-Human Study of MS201408-0005A as Single Agent and in Combinations (NCT03306420) | EMD Serono Research & Development Institute, Inc. | 2017-10-03 |
| Phase IIb Study of Evobrutinib in Subjects With Rheumatoid Arthritis (NCT03233230) | EMD Serono Research & Development Institute, Inc. | 2017-09-18 |
| M3541 in Combination With Radiotherapy in Solid Tumors (NCT03225105) | EMD Serono Research & Development Institute, Inc. | 2017-09-06 |